The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.

The new-look DCB was designed to provide care with a significantly lower drug load than similar devices. 

The coroner is concerned that the medication's rare side effects do not receive enough attention when it is prescribed to patients. 

While cardiac damage reverses in many patients following treatment, it can actually continue to get worse in others. 

"Psychologists have had little involvement in the care of cardiac patients but this needs to change," one researcher said in a statement. 

An ear clip device has been shown to effectively stimulate nerves to treat postural tachycardia syndrome.

A new retrospective study from the Mayo Clinic focused on patients with no other need for anticoagulation.

The Drug Price Negotiation Program already has changed how the company considers the development of future oncology programs and medications. 

This is the first time that the task force has recommended screening for anxiety disorders in an asymptomatic adult population.